Your browser is no longer supported. Please, upgrade your browser.
DTIL Precision BioSciences, Inc. daily Stock Chart
Precision BioSciences, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own0.30% Shs Outstand51.91M Perf Week2.35%
Market Cap355.14M Forward P/E- EPS next Y-2.11 Insider Trans0.00% Shs Float43.50M Perf Month18.31%
Income-101.20M PEG- EPS next Q-0.66 Inst Own49.10% Short Float6.45% Perf Quarter-11.20%
Sales19.50M P/S18.21 EPS this Y-135.60% Inst Trans-0.84% Short Ratio4.22 Perf Half Y-6.06%
Book/sh1.65 P/B4.23 EPS next Y9.40% ROA-45.30% Target Price- Perf Year10.44%
Cash/sh2.49 P/C2.80 EPS next 5Y- ROE-81.80% 52W Range4.45 - 23.67 Perf YTD-49.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.51% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low56.68% ATR0.49
Employees220 Current Ratio4.00 Sales Q/Q-79.60% Oper. Margin- RSI (14)60.04 Volatility6.64% 7.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.20% Profit Margin- Rel Volume0.47 Prev Close6.85
ShortableYes LT Debt/Eq0.00 EarningsAug 13 BMO Payout- Avg Volume665.31K Price6.98
Recom1.60 SMA206.26% SMA5015.72% SMA200-4.58% Volume314,838 Change1.90%
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
Apr-22-19Initiated Jefferies Buy
Apr-22-19Initiated Goldman Buy
Apr-22-19Initiated Barclays Overweight
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Sep-28-20 07:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 07:21AM  
Sep-09-20 07:00AM  
Sep-02-20 07:00AM  
Aug-19-20 07:00AM  
Aug-13-20 10:35AM  
Aug-06-20 12:30PM  
Aug-03-20 07:00AM  
Jul-17-20 10:29AM  
Jul-06-20 07:00AM  
Jul-05-20 04:33PM  
Jun-08-20 07:00AM  
May-26-20 04:01PM  
May-18-20 06:34AM  
May-15-20 08:52AM  
May-08-20 12:30PM  
May-07-20 07:00AM  
Apr-28-20 04:45PM  
Apr-27-20 12:31PM  
Apr-15-20 07:00AM  
Apr-07-20 07:00AM  
Apr-02-20 02:54PM  
Mar-12-20 07:26AM  
Mar-11-20 07:24AM  
Mar-10-20 07:05AM  
Feb-21-20 07:00AM  
Jan-13-20 07:00AM  
Jan-06-20 07:00AM  
Dec-31-19 03:15PM  
Dec-30-19 03:40PM  
Dec-19-19 06:28PM  
Dec-09-19 04:19PM  
Nov-27-19 09:24AM  
Nov-13-19 07:00AM  
Nov-12-19 07:15AM  
Nov-06-19 09:01AM  
Oct-31-19 12:20PM  
Oct-30-19 10:34AM  
Oct-03-19 10:11AM  
Sep-30-19 07:58AM  
Sep-26-19 06:30AM  
Sep-23-19 06:30AM  
Sep-17-19 07:10AM  
Sep-16-19 06:30AM  
Sep-04-19 06:30AM  
Aug-28-19 06:30AM  
Aug-14-19 04:30PM  
Jul-22-19 08:23AM  
Jul-18-19 01:04PM  
Jul-10-19 03:00PM  
Jul-05-19 01:12PM  
Jun-23-19 08:53PM  
Jun-12-19 06:30AM  
Jun-11-19 06:00AM  
May-29-19 06:30AM  
May-22-19 01:31PM  
May-14-19 06:30AM  
May-09-19 06:30AM  
Apr-29-19 07:05PM  
Apr-24-19 06:30AM  
Apr-17-19 05:30AM  
Apr-04-19 01:55PM  
Apr-01-19 04:05PM  
Mar-29-19 03:05PM  
Mar-27-19 05:50PM  
Mar-24-19 05:16PM  
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANSARI ABIDChief Financial OfficerJun 15Option Exercise1.208,78310,540144,401Jun 17 04:00 PM
ANSARI ABIDChief Financial OfficerMay 15Option Exercise1.209,66111,576135,618May 19 07:17 AM
JANTZ DEREKChief Scientific OfficerApr 14Option Exercise1.184,3925,1833,862,738Apr 15 05:26 PM
ANSARI ABIDChief Financial OfficerJan 06Option Exercise1.2020,20024,187123,845Jan 08 08:23 AM
Heery ChristopherChief Medical OfficerDec 19Buy12.082,48530,0212,485Dec 20 04:44 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.